Filing Details
- Accession Number:
- 0001225208-13-005021
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-02-21 18:06:45
- Reporting Period:
- 2013-02-20
- Filing Date:
- 2013-02-21
- Accepted Time:
- 2013-02-21 18:06:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 14272 | Bristol Myers Squibb Co | BMY | Pharmaceutical Preparations (2834) | 220790350 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1198959 | M James Cornelius | Bristol-Myers Squibb Company 345 Park Avenue New York NY 10154 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.10 Par Value | Disposition | 2013-02-20 | 10,000 | $36.87 | 1,091,218 | No | 4 | S | Direct | |
| Common Stock, $0.10 Par Value | Disposition | 2013-02-21 | 10,000 | $36.67 | 1,081,218 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012.
- The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.70 to $36.98, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.59 to $36.76, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
